Effects of Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Ryan, Donna H.
Gadde, Kishore
Wilson, Leland F.
Troupin, Barbara
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A491 / A491
页数：1
相关论文
共 50 条
  • [21] The efficacy and tolerability of topiramate controlled-release in the treatment of obese type 2 diabetes (T2DM) managed with diet or metformin
    Rosenstock, J
    Hollander, P
    Gadde, KM
    Leung, AT
    Sun, X
    Strauss, R
    DIABETES, 2005, 54 : A12 - A12
  • [22] Weight Loss (WL) With Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine Aminotransferase (ALT)
    Klein, Samuel
    Najarian, Thomas
    Troupin, Barbara
    Day, Wesley W.
    OBESITY, 2011, 19 : S177 - S177
  • [23] Diabetes Prevention and Normalization of Fasting Glucose in Subjects with Prediabetes Using Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) in a 2-Year Weight Loss Intervention
    Ryan, Donna H.
    Garvey, Timothy
    Troupin, Barbara
    Day, Wesley W.
    DIABETES, 2011, 60 : A509 - A509
  • [24] Once-daily, low-dose, controlled-release phentermine/topiramate results in significant clinical improvements in overweight/obese patients with type 2 diabetes
    Garvey, W. T.
    Troupin, B.
    Day, W. W.
    DIABETOLOGIA, 2010, 53
  • [25] LOW-DOSE CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) RESULTS IN SIGNIFICANT WEIGHT LOSS AND IMPROVES ATHEROSCLEROTIC BIOMARKERS IN OVERWEIGHT/OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
    Troupin, B.
    Hankin, C. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S39 - S39
  • [26] Clinically Meaningful Weight-Loss Outcomes With Low-Dose Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects
    Gadde, Kishore M.
    Peterson, Craig
    Day, Wesley W.
    OBESITY, 2010, 18 : S153 - S153
  • [27] Low-Dose, Controlled-Release Phentermine/Topiramate (PHEM/TPM CR) Reduces Adiposity, Improves Cardiometabolic Risk in Overweight/Obese Patients
    Gallagher, Dympna
    Punyanitya, Mark
    Bowden, Charles
    Peterson, Craig
    OBESITY, 2010, 18 : S154 - S154
  • [28] Decreased progression to diabetes in subjects with prediabetes after 2 years of treatment with controlled-release phentermine/topiramate
    Garvey, W. T.
    Troupin, B.
    Day, W. W.
    DIABETOLOGIA, 2011, 54 : S371 - S371
  • [29] Regional effects of type 2 diabetes mellitus (T2DM) on neurodegeneration
    Moran, C.
    Phan, T. G.
    Beare, R. J.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 : 20 - 20
  • [30] Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
    Garvey, W. Timothy
    Ryan, Donna H.
    Bohannon, Nancy J. V.
    Kushner, Robert F.
    Rueger, Miriam
    Dvorak, Roman V.
    Troupin, Barbara
    DIABETES CARE, 2014, 37 (12) : 3309 - 3316
12345